Telomerase activity and survival of patients with node-positive breast cancer

Journal of the National Cancer Institute

Volumn 89, Issue 24, 1997, Pages 1874-1881

  Clark, Gary M ^a,c   Osborne, C Kent ^a   Levitt, Daniel ^b,d   Wu, Fred ^b,e   Kim, Nam W ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b GERON CORPORATION   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d PROTEIN DESIGN LABS INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PLOIDY; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 0031442702     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.24.1874     Document Type: Article

References (49)

1. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-73.
2. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence. (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988;85:6622-6.
3. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973;41:181-90.
4. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972;239:197-201.
5. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256: 271-82.
6. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990;345:458-60.
7. Lindsey J, McGill N, Lindsey LA, Green DK, Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991;256:45-8.
8. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993;52:661-7.
9. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.
10. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989;59: 521-9.
11. Counter CM, Botelho FM. Wang P, Harley CB, Baccherti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J Virol 1994; 68:3410-4.
12. Greider CW, Blackburn EB. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987;51:887-98.
13. Greider CW. Telomeres, telomerase and senescence. Bioessays 1990;12:363-9.
14. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A 1994;91: 2900-4.
15. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995;55: 2533-6.
16. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995;85:2315-20.
17. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, et al. Telomerase activity in gastric cancer. Cancer Res 1995;55:3258-62.
18. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996;88:116-22.
19. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
20. Mehle C, Piatyszek MA, Ljungberg B, Shay JW, Roos G. Telomerase activity in human renal cell carcinoma. Oncogene 1996;13: 161-6.
21. Rhyu MS. Telomeres, telomerase, and immortality, J Natl Cancer Inst 1995;87:884-94.
22. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;8: 66-71.
23. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bava GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56: 218-22.
24. Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T, et al. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1995;1: 1245-51.
25. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.
26. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, et al. DNA ploidy. S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993;28:9-20.
27. Dressier LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988;61:420-7.
28. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322: 297-302.
29. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
30. Klijn JG, Berns PM, Schmitz PI, Foekens JA. Epidermal growth factor receptor (EGF-R) in clinical breast cancer: update 1993. Endocr Rev 1993;1:171-4.
31. Kim NW. Assay method for the telomeric repeat amplification protocol (TRAP). Retinoids Today and Tomorrow 1995;40-3.
32. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Wright WE, et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Science 1995;17:1-15.
33. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by Telomeric Repeat Amplification Protocol (TRAP). Nucleic Acids Res 1997;25:2595-7.
34. Kaplan EL, Meier PL. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
35. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984.
36. Hilsenbeck SG, Clark GM. Practical p-value adjustment for optimally selected cutpoints. Stat Med 1996;15:103-12.
37. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-200.
38. Sugino T, Yoshida K, Bolodeoku J, Tahara H, Buley I, Manek S, et al. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. Int J Cancer 1996;69:301-6.
39. Nawaz S, Hashizumi TL, Markham NE, Shroyer AL, Shroyer KR. Telomerase expression in human breast cancer with and without lymph node metastases. Am J Clin Pathol 1997;107: 542-7.
40. Landberg G, Nielsen NH, Nilsson P, Emdin SO, Cajander J, Roos G. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res 1997;57: 549-54.
41. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO Journal 1992;11:1921-9.
42. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 1994;59:307-15.
43. Harley CB, Kim NW. Telomerase and cancer. In: DeVita VJ, Hellman S, Rosenberg S, editors. Important advances in oncology 1996. Philadelphia: Lippincott-Raven, 1996: 57-67.
44. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-9.
45. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M. Hiyama E, Piatyszek MA, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995: 155:3711-5.
46. Yashima K, Piatyszek MA, Saboorian HM, Virmani AK, Brown D, Shay JW, et al. Telomerase activity and in situ telomerase RNA expression in malignant and non-malignant lymph nodes. J Clin Pathol 1997;50: 110-7.
47. Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993;71(6 Suppl):2157-62.
48. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326:1756-61.
49. ASCO Tumor Marker Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.